These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 234788)

  • 1. Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy.
    Chester SJ; Esparza AR; Albala MM
    Cancer Res; 1975 Mar; 35(3):634-6. PubMed ID: 234788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Albala MM
    Cancer Res; 1975 Mar; 35(3):637-9. PubMed ID: 234789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
    Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
    Kende M; Keys LD; Gaston M; Goldin A
    Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigation of graft-versus-host disease in mice by treatment of donors with bacterial endotoxin.
    Rose WC; Rodey GE; Rimm AA; Truitt RL; Bortin MM
    Exp Hematol; 1976 Mar; 4(2):90-6. PubMed ID: 4335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide.
    Truitt RL; Rose WC; Rimm AA; Bortin MM
    Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.
    Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Maeda T; Ando T; Nomoto K
    J Immunol; 1991 Mar; 146(5):1402-9. PubMed ID: 1671578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of graft-versus-host reaction on the immune response to alloantigens and growth of a syngeneic tumor.
    Zaleski M
    Exp Hematol; 1975 Jan; 3(1):12-21. PubMed ID: 238866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia for AKR spontaneous leukemia-lymphoma.
    Truitt RL; Rimm AA; Saltzstein EC; Rose WC; Bortin MM
    Transplant Proc; 1976 Dec; 8(4):569-74. PubMed ID: 11589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy and combined chemo-immunotherapy in transplantable leukaemia of AKR mice (TAL); occurrence of natural killers.
    Schneiberg K; Rytwiński K; Tabeńska J
    Haematologia (Budap); 1981; 14(2):137-46. PubMed ID: 7274781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft versus leukemia. 3. Apparent independent anthost and antileukemia activity of transplanted immunocompetent cells.
    Bortin MM; Rimm AA; Saltzstein EC; Rodey GE
    Transplantation; 1973 Sep; 16(3):182-8. PubMed ID: 4147030
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
    Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review.
    Fefer A
    Isr J Med Sci; 1973 Mar; 9(3):350-65. PubMed ID: 4145461
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of tumors as a result of graft-versus-host reaction.
    Cornelius EA
    Exp Hematol; 1973; 1(3):135-49. PubMed ID: 4153858
    [No Abstract]   [Full Text] [Related]  

  • 17. Graft versus leukemia for "cell cure" of long-passage AKR leukemia after chemoradiotherapy.
    Saltzstein EC; Glasspiegel JS; Rimm AA; Giller RH; Bortin MM
    Cancer Res; 1972 Aug; 32(8):1658-62. PubMed ID: 4402951
    [No Abstract]   [Full Text] [Related]  

  • 18. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia.
    Okunewick JP; Meredith RF; Raikow RB; Brozovich BJ; Magliere K
    Exp Hematol; 1981 Aug; 9(7):754-65. PubMed ID: 7032959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive effects of sulfato-trans-(-)-1,2-diaminocyclohexaneplatinum(II).
    Khan A; Hogan S; Hill JM
    Cancer Res; 1979 Sep; 39(9):3476-8. PubMed ID: 38904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.